
July PPI: U.S. wholesale prices rose 0.9%, much more than expected
Aug. 14 (UPI) -- The threat of inflation to the U.S. economy may be looming after a Bureau of Labor Statistics report Thursday showed a jump in wholesale prices
The Producer Price Index for final demand rose a seasonally adjusted 0.9% in July, a surge absent in June when such prices stayed flat after having risen only 0.4% in May.
Even more noticeable is the index for the total of final demand prices without adjustment, which saw a 3.3% increase for the 12 months ending in July, the largest 12-month upswing since rising 3.4% in February.
Within the final demand spectrum, three-quarters of the advance comes from the index for final demand services, such as transportation and warehousing, which rose 1.1%, the largest such advance since rising to 1.3% in March of 2022.
Prices for final demand goods increased 0.7% when measured with the inclusion of foods, energy, and trade services. Without those items, the rise is just a slightly smaller 0.6%, the largest increase since a 0.9% leap that also took place in March of 2022.
The index for final demand services also rose, moving 1.1% up in July, the biggest jump since that clearly rough fiscal month of March in 2022, when such services rose 1.3%.
A deeper dive into the price windup showed 30% of the July jump in final demand services is due to the margins for machinery and equipment wholesaling, which increased 3.8%. Additionally, 40% of the broad-based increase in July can be credited to the index for final demand foods, up 1.4%, and among the foods, prices for fresh and dry vegetables soared a whopping 38.9% percent.
Another major player in the overall July increase comes from the diesel fuel index, which ascended 11.8% and is responsible for more than 50% of the month's increase in prices for processed goods for intermediate demand. The index for raw milk moved up 9.1%, accountable for more than 30% of the July increase in prices for unprocessed goods for intermediate demand.
The Producer Price Index's data includes key details on overall prices, and is combined with information taken from the Consumer Price Index to fill out the Commerce Department's personal consumption expenditures price index, the government's chief inflation forecasting scale.
The Consumer Price Index had only ticked upwards a seasonally adjusted 0.2% in July and 2.7% on a 12-month basis, a bit less than of an impact than expected with the Trump administration's tariffs in action.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
PolyPeptide Group First Half 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore PolyPeptide Group's Fair Values from the Community and select yours PolyPeptide Group (VTX:PPGN) First Half 2025 Results Key Financial Results Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened by 133% from 1H 2024). €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period PolyPeptide Group Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 40%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Performance of the Swiss Life Sciences industry. The company's shares are up 25% from a week ago. Risk Analysis Before we wrap up, we've discovered 1 warning sign for PolyPeptide Group that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
an hour ago
- Yahoo
Why Investors Were So Fired Up About First Solar Stock on Friday
Key Points Data center operators are unhappy with potential changes to federal incentives for green energy solutions. A group of them are lobbying the Trump administration to leave these incentives alone for now. 10 stocks we like better than First Solar › The solar industry has struggled mightily for years to achieve meaningful growth and post net profits. During the Biden administration, the green energy sector as a whole received something of a break in the 2022 Inflation Reduction Act, with a slew of tax incentives for building out alternative-energy solutions. In its attempt to reverse this, President Donald Trump has tasked his administration to make the current subsidies harder to obtain. Thankfully for green energy companies, a theoretically influential lobbying group stepped in on Friday to push back against this effort. Numerous solar stocks popped on the news, including First Solar (NASDAQ: FSLR), which rose a sturdy 11% by market close. A mighty lob by a lobbying group The business grouping behind Friday's pushback is the Data Center Coalition. News broke that the coalition sent a formal request to Treasury Secretary Scott Bessent to maintain the subsidy policy as it is, rather than changing it. The organization -- which lists as members Amazon, Oracle, and CoreWeave, among other prominent tech companies -- told Bessent that any regulatory roadblock limiting green energy solutions will hamper the development of artificial intelligence (AI). Many data center operators are currently building out their facilities to handle the vastly increased resource demands of AI. To do so, they require more energy, hence their support of renewable sources like solar. Does the silence speak volumes? Bessent hasn't yet publicly responded to the coalition's lobbying effort, nor has anyone else in the Trump administration. But investors seem convinced that they've not only digested the letter, they're taking it seriously, since the organization behind it has many prominent members who drive the U.S. economy. Should you invest $1,000 in First Solar right now? Before you buy stock in First Solar, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and First Solar wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, First Solar, and Oracle. The Motley Fool has a disclosure policy. Why Investors Were So Fired Up About First Solar Stock on Friday was originally published by The Motley Fool


New York Times
2 hours ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.